AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01821001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Bromocriptine
Description: Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
Study NCT02630511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo consists of inhaling humidified air
Study NCT02630511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Study NCT02630511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01805843 — intervention group
Intervention type: OTHER
Intervention: Echo, exercise echo, and if indicated, right heart catheter
Description: routine echocardiography and special measurements of the right heart are performed at rest and during exercise
Study NCT04352101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion XL
Description: Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
Study NCT02489942 — intervention group
Intervention type: DRUG
Intervention: Jardiance
Description: Empagliflozin
Study NCT00554671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self efficacy
Description: Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
Study NCT03569371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 administered once daily orally with water without regard to food for 8 weeks.
Study NCT01791738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetabular positioning system
Description: Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
Study NCT04114253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT03422341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between GenePOC CR and Reference Method
Description: The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
Study NCT03422341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between GenePOC CR and Reference Method
Description: The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
Study NCT01879228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Study NCT00694902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
Study NCT01879228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Study NCT01468766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive resistance training
Description: 2x60 minutes per week for 12 weeks
Study NCT01468766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive muscle relaxation training (Jacobson method)
Description: 2x60 minutes per week for 12 weeks
Study NCT04780386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805
Description: orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
Study NCT04780386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1805-R1and NVP-1805-R2
Description: orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
Study NCT00668603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol
Description: 2mg oral daily for 6 months
Study NCT00668603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol + medroxyprogeterone acetate
Description: 2mg E2 + 5mg MPA daily for 6 months
Study NCT00721695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302
Description: OMS302 Irrigation Solution
Study NCT00721695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMS302-PE
Description: OMS302-PE HCI Irrigation Solution
Study NCT00721695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
Study NCT02935465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
Study NCT02935465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
Study NCT04585516 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopy
Description: Colonoscopy or gastroscopy
Study NCT00668603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-b-estradiol hemihydrate
Description: 1 mg skin gel daily for 6 months
Study NCT00668603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill + gel
Description: placebo daily for 6 months
Study NCT02117180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FODMAP's diet
Description: The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
Study NCT01168024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CINCOR™ System and contrast conservation unit (CCS-1)
Description: Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
Study NCT01168024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care plus peri-procedural hydration
Description: The control group will receive a peri and post-procedural hydration rate.
Study NCT00321867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graft augmented posterior repair
Description: Posterior repair with graft
Study NCT00321867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Native tissue repair
Study NCT04647123 — intervention group
Intervention type: OTHER
Intervention: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Description: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
Study NCT04274985 — intervention group
Intervention type: OTHER
Intervention: Questionnaire application
Description: Patients will complete the mentioned questionnaires.
Study NCT02647021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
Study NCT02647021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
Study NCT02647021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic + Lower Body Exercise
Description: A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
Study NCT00984386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
Study NCT00984386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
Study NCT00984386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
Study NCT00984386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zesteem
Description: Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
Study NCT00984386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal placebo, 100μl administered once before punch biopsy
Study NCT00942669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStrip OTC(TM)
Description: self contained SAS screening device
Study NCT02471898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Study NCT02471898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02631434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sit-to-stand test
Study NCT02631434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: six-minutes walking test
Study NCT03702192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR
Description: novel antithrombotic management protocol
Study NCT03993314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
Study NCT03993314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
Study NCT04501874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMB-001
Description: 720 mg metyrapone/24 mg oxazepam mg BID
Study NCT04501874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EMB-001 Placebo
Description: Inactive comparator
Study NCT00519090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
Study NCT00519090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107)
Description: Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
Study NCT01864746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib PD-0332991
Description: palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
Study NCT01864746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
Study NCT03029572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet supplementation
Description: Micronutriment supplementation therapy
Study NCT03029572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Roux-en-Y gastric bypass provided in both arms.
Study NCT03029572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Roux-en-Y gastric bypass provided in both arms.
Study NCT02473341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated
Study NCT02473341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated.
Study NCT01319422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Comparison of different dosages and schedules of drug
Study NCT02361307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seamless ADL training
Description: The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
Study NCT02361307 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional ADL training
Description: The control group receive the conventional ADL training programme
Study NCT00592423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Positive Airway Pressure during MRI
Description: 10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
Study NCT00784225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium
Description: 200 mcg daily for 7-12 years
Study NCT00784225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: 400 IU daily by mouth for 7-12 years
Study NCT00784225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin E placebo
Description: daily for 7-12 years
Study NCT00784225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin E placebo
Description: daily for 7-12 years
Study NCT00784225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium placebo
Description: daily for 7-12 years
Study NCT04352101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
Study NCT04767399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: protaper next
Description: rotary systems used on patients need root canal treatment
Study NCT02561442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Study NCT02561442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Study NCT01378767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Krill oil supplementation
Description: During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
Study NCT01378767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil supplementation
Description: During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
Study NCT00784225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: selenium placebo
Description: daily for 7-12 years
Study NCT03529981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuned Vibroacoustic Stimulation (TVS)
Description: TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
Study NCT03529981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no active intervention
Description: No intervention will be administered
Study NCT02531061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes.
Study NCT00015912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given IV
Study NCT00015912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00015912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02620228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP Biopsy System
Description: BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
Study NCT01061073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omexel
Study NCT01061073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spasfon
Study NCT02377258 — intervention group
Intervention type: OTHER
Intervention: Non Interventional
Study NCT03684499 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fluid supplementation
Description: The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
Study NCT03684499 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: breast feeding
Description: The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.(Bandyopadhyay et al, 2017)
Study NCT00845598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine , fluticasone
Description: Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily
Study NCT00845598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
Study NCT02525497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FM peritoneal dialysis machine
Description: FM peritoneal dialysis machine APD 10L/10h
Study NCT02525497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOMECHOICE peritoneal dialysis machine
Description: HOMECHOICE peritoneal dialysis machine APD 10L/10h
Study NCT01912521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mfangano Health Net Microclinic Program
Description: Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
Study NCT03019809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF for Conditioning before HSCT.
Description: Mobilization of hematopoietic stem (HSC) into circulation
Study NCT03019809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plerixafor for Conditioning before HSCT.
Description: Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
Study NCT03717558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin T1
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
Study NCT03717558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin T1
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
Study NCT03717558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin T2
Description: Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol